Form D · Pharmaceuticals

Verona Pharma plc

London, X0 · CIK 0001657312

Offering snapshot reported Jul 30, 2020 · SEC filing

Reported sold
$200M
Offering amount: $200M
Investors reported
43
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 22, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 30, 2020Initial$200,155,041No comparison43SEC filing
Jul 20, 2016Initial$44,524,058No comparison8SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$12M
Finders' fees
$0
Form D file number
021-372077

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
JEFFERIES LLC2347
CANACCORD GENUITY LLC1020
WEDBUSH SECURITIES INC.877
BTIG, LLC122225

Source: Form D, filed Jul 30, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Ken Cunningham Director
David Ebsworth Director
Martin Edwards Director
Rishi Gupta Director
Mark W. Hahn Executive
Patrick Humphrey Director
Jan Anders Karlsson Director, Executive
Kenneth Newman Executive
Claire Poll Executive
Kathleen Rickard Executive
Mahendra Shah Director
Andrew Sinclair Director
Vikas Sinha Director
Peter Spargo Executive
Anders Ullman Director
David Zaccardelli Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
3 More London Riverside
London, X0, SE1 2RE